PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

SMC expands guidance for Lokelma to emergency care settings

New access to treatment involves adult patients with hyperkalaemia across Scotland.

AstraZeneca has announced that the Scottish Medicines Consortium (SMC) has updated advice for Lokelma for adult patients with hyperkalaemia in Scotland.

The advice to the SMC now means patients can access Lokelma – also known as sodium zirconium cyclosilicate (SZC) – in emergency care settings for the treatment of acute, life-threatening hyperkalaemia alongside standard of care.

Consequently, SZC is accepted for restricted use within NHS Scotland within outpatient care for hyperkalaemia patients with chronic kidney disease or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system therapy.

The updated SMC advice addresses a particular need in Scotland for access to potassium-binding treatments that removes potassium from the blood. Meanwhile, the National Institute for Health and Care Excellence (NICE) for England, Wales and Northern Ireland issued a positive recommendation for SZC in the emergency care setting and therefore, this updated SMC advice also addresses potential equality of care issues in enabling access for Scottish patients.

“For adult patients in Scotland who develop high potassium levels, today’s announcement will be an extremely welcome milestone,” Dr Iain Macintyre, consultant nephrologist and clinical pharmacologist at the New Royal Infirmary of Edinburgh NHS Lothian, explained.

He added: “Risk of developing hyperkalaemia is increased for patients taking life-saving cardio-renal medications and the decision today from the Scottish Medicines Consortium means that patients with this condition will now have access to an important treatment option in the emergency care setting when the condition is potentially life-threatening.”

Hyperkalaemia is a medical condition of elevated potassium levels in the blood, and in severe cases, it may lead to cardiac arrest and death. Furthermore, there is an increased risk of developing hyperkalaemia in patients with chronic kidney disease and heart failure compared to the general population.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026